HHG GROUP
Language
Direction Contact us
Mitera MENU
Kosmidis Paraskevas

Kosmidis Paraskevas Internist Oncologist

Director, 2nd Internal Medicine - Oncology Clinic HYGEIA Hospital

Education & Academic Qualifications

  • Dr Kosmidis received his medical degree from the Medical School of Athens University in Athens , Greece . He completed his training in Internal Medicine at Sinai Hospital in Detroit , Michigan , U.S.A. (1976).
  • He served as a Fellow in Hematology – Oncology at Wayne State University and Henry Ford Hospital , both also in Detroit (1976 – 1979) . He is American Board certified in Internal Medicine , Hematology and Medical Oncology , as well as European Board certified in Medical Oncology.

 

Doctoral thesis

  • University of Athens

Fellowship in Societies, Membership in Journal Editorial Committees

  • Dr Kosmidis is a founding member of the Hellenic Medical Oncology Society , as well as the Hellenic Cooperative Oncology Group, the Hellenic Foundation for Cancer Research, the Hellenic Society of Gastrointestinal Oncology and principal investigator in major studies both in Greece and abroad . He is the author or co-author of several books and articles in leading international oncology journals . He serves at the Editorial Board in many oncology journals of the world.

Work Experience

  • Prior to his current position, he received appointments to serve as Head of the Second Department of Medical Oncology at St Anargiri Cancer Hospital in Athens (1981 – 1985) and at “METAXA” Cancer Hospital in Piraeus (1985 – 1997).

Honors & Awards

Dr Kosmidis has been awarded by the Academy of Athens twice. Dr Kosmidis has been awarded by many Oncology Societies worldwide and he is honorary member of ESMO and the Italian Medical Oncology Association.

He has been awarded by 

  • Hellenic Society of Medical Oncology

  • Hellenic Society of Gastrointestinal Oncology

  • Dr Kosmidis was the President of the 23rd European Society of Medical Oncology (ESMO) Congress in Athens, 1998 and was elected as the Chairman of The National Representative’s Committee in ESMO .

  • Dr Kosmidis has been the President of the European Society of Medical On-cology for the years 2004 – 2005. Since 1st of January 2006 he has served the society from the position of Past-President. He was also the Chairman of the ESMO Foundation up to December 2007. Dr Kosmidis was the President of the Scientific Committee of “HYGEIA” Hospital. 

 

Books

  • Gastrointestinal Oncology

  •  Oncology Emergencies

  •  Imaging Oncology

  •  PET-CT Atlas in Lymphomas

  •  Principles and Practice in Lung Cancer

 

Recent Publications

  • VASCULAR ENDOTHELIAL GROWTH FACTOR POLYMORPHISMS AND CLINICAL OUTCOME IN PATIENTS WITH METASTATIC BREAST CANCER TREATED WITH WEEKLY DOCETAXEL, Koutras AK, Kotoula V, Papadimitriou C, Dionysopoulos D, Zagouri F, Kalofonos HP, Kourea HP, Skarlos DV, Samantas E, Papadopoulou K, Kosmidis P, Pectasides D, Fountzilas G.Pharmacogenomics J. 2014 Jun;14(3):248-55. doi: 10.1038/tpj.2013.36. Epub 2013 Sep 24.

  • DOSE-DENSE SEQUENTIAL ADJUVANT CHEMOTHERAPY FOLLOWED, AS INDICATED, BY TRASTUZUMAB FOR ONE YEAR IN PATIENTS WITH EARLY BREAST CANCER: FIRST REPORT AT 5-YEAR MEDIAN FOLLOW-UP OF A HELLENIC COOPERATIVE ONCOLOGY GROUP RANDOMIZED PHASE III TRIAL. G. Fountzilas, U. Dafni, C. Papadimitriou, E. Timotheadou, H. Gogas, A.G. Eleftheraki, I. Xanthakis, C.Christodoulou, A. Koutras, C.N. Papandreou, P. Papakostas, S. Miliaras,  C. Markopoulos, C. Dimitrakakis, P.Korantzopoulos, C. Karanikiotis, D. Bafaloukos, P. Kosmidis, E. Samantas, I. Varthalitis, N. Pavlidis, D.Pectasides, M.A. Dimopoulos BMC Cancer, 2014 Jul 15;14:515. doi: 10.1186/1471-2407-14-515

  • SAFETY AND TOLERABILITY OF ANTHRACYCLINE-CONTAINING ADJUVANT CHEMOTHERAPY IN ELDERLY HIGH-RISK BREAST CANCER PATIENTS Vasilios Karavasilis, Christos Papadimitriou, Helen Gogas, George Kouvatseas, George Pentheroudakis, Angelos Koutras, Christos Christodoulou, Dimitrios Bafaloukos, Epaminontas Samantas, Nikolaos Pisanidis, Pavlos Papakostas, Gerasimos Aravantinos, Charisios Karanikiotis, Paris Kosmidis, Dimitrios Pectasides, Meletios-Athanassios Dimopoulos, George Fountzilas Breast Cancer Collection, Submitted/to aposyrame 8/2014

  • EXPRESSION OF ANGIOGENESIS-RELATED FACTORS IN METASTATIC BREAST CARCINOMA TREATED WITH WEEKLY DOCETAXEL. A HELLENIC COOPERATIVE ONCOLOGY GROUP (HECOG) STUDY Helen P. Kourea, Vassiliki Kotoula, Angelos Koutras, Zoi Alexopoulou, Irene Papaspirou, Dimosthenis V. Skarlos, Ioannis Efstratiou, Mattheos Bobos, Flora Zagouri, Pavlos Papakostas, Dimitrios Pectasides, Sofia Chrisafi, Ioannis Varthalitis, Gerasimos Aravantinos, Paris Kosmidis, Dimitrios Bafaloukos, Chrisoula D Scopa, George Fountzilas Histology and Histopathology, Under revision

  • INTACT OR BROKEN-APART RNA: AN ALTERNATIVE CONCEPT FOR ALK FUSION SCREENING IN NON-SMALL CELL LUNG CANCER (NSCLC) Vassiliki Kotoula; Mattheos Bobos; Maria Vassilakopoulou; Eleftheria Tsolaki; Sofia Chrisafi; Amanda Psyrri; George Lazaridis; Kyriaki Papadopoulou; Ioannis Efstratiou; Catherine Michail-Strantzia; Larisa V Debelenko; Paris Kosmidis; George Fountzilas Appl Immunohistochem Mol Morphol. 2015 Jan;23(1):60-70. doi: 10.1097/PAI.0000000000000028.

  • DOCETAXEL AND INTERMITENT ERLOTINIB IN PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER; THE DOPERLO STUDY FROM THE HELLENIC COOPERATIVE ONCOLOGY GROUP Karavasilis Vasilios, Paris Kosmidis, Kostas Syrigos, Meletios A. Dimopoulos, Vassiliki Kotoula, Dimitrios Pectasides, Ioannis Boukovinas, George Klouvas, Christos N. Papandreou, George Fountzilas, Evangelos Briasoulis Anticancer Research, 2014 Oct;34(10):5649-55.

  • IMPACT OF TUMOR ANGIOGENIC PROFILE ON THE OUTCOME OF PATIENTS WITH METASTATIC BREAST CARCINOMA TREATED WITH WEEKLY DOCETAXEL. A HELLENIC COOPERATIVE ONCOLOGY GROUP (HECOG) STUDY Helen P. Kourea, Vassiliki Kotoula, Angelos Koutras, Zoi Alexopoulou, Irene Papaspirou, Dimosthenis V. Skarlos, Ioannis Efstratiou, Mattheos Bobos, Flora Zagouri, Pavlos Papakostas, Dimitrios Pectasides, Sofia Chrisafi, Ioannis Varthalitis, Gerasimos Aravantinos, Paris Kosmidis, Dimitrios Bafaloukos, Chrisoula D. Scopa and George Fountzilas Histol Histopathol (2015) 30: 1129-1141

  • SIGNIFICANCE OF THE TYPE OF PIK3CA MUTATIONS IN PATIENTS WITH EARLY BREAST CANCER TREATED WITH ADJUVANT CHEMOTHERAPY: A Hellenic Cooperative Oncology Group (HeCOG) study George Papaxoinis, Vassiliki Kotoula, Zoi Alexopoulou, Konstantine T. Kalogeras, Flora Zagouri, Eleni Timotheadou, Helen Gogas, George Pentheroudakis, Christos Christodoulou, Angelos Koutras, Dimitrios Bafaloukos, Gerasimos Aravantinos, Pavlos Papakostas, Elpida Charalambous, Kyriaki Papadopoulou, Ioannis Varthalitis, Ioannis Efstratiou, Thomas Zaramboukas, Helen Patsea, Chrisoula D. Scopa, Maria Skondra, Paris Kosmidis, Dimitrios Pectasides, George Fountzilas PLoS One. 2015 Oct 9;10(10):e0140293. doi: 10.1371/journal.pone.0140293. eCollection 2015

  • TUMORS WITH HIGH-DENSITY TUMOR INFILTRATING LYMPHOCYTES CONSTITUTE A FAVORABLE ENTITY IN BREAST CANCER: A POOLED ANALYSIS OF FOUR PROSPECTIVE ADJUVANT TRIALS Vassiliki Kotoula, Kyriakos Chatzopoulos , Sotiris Lakis , Zoi Alexopoulou , Eleni Timotheadou , Flora Zagouri , George Pentheroudakis , Helen Gogas , Eleni Galani , Ioannis Efstratiou , Thomas Zaramboukas , Angelos Koutras, Gerasimos Aravantinos , Epaminontas Samantas , Amanda Psyrri , Helen Kourea , Mattheos Bobos , Pavlos Papakostas , Paris Kosmidis , Dimitrios Pectasides , George Fountzilas Oncotarget. 2015 Oct 25. doi: 10.18632/oncotarget.6231. [Epub ahead of print]

  • SAFETY AND TOLERABILITY OF ANTHRACYCLINE-CONTAINING ADJUVANT CHEMOTHERAPY IN ELDERLY HIGH-RISK BREAST CANCER PATIENTS Vasilios Karavasilis, Christos Papadimitriou, Helen Gogas, George Kouvatseas, George Pentheroudakis, Angelos Koutras, Christos Christodoulou, Dimitrios Bafaloukos, Epaminontas Samantas, Nikolaos Pisanidis, Pavlos Papakostas, Gerasimos Aravantinos, Charisios Karanikiotis, Paris Kosmidis, Dimitrios Pectasides, Meletios-Athanassios Dimopoulos, George Fountzilas Clinical Breast Cancer- In press

  • COMPARISON OF THE CLINICAL TREATMENT SCORE (CTS) WITH THE ADJUVANT ONLINE SCORE AND THE RISK FOR RECURRENCE SCORE FOR ESTIMATING PROGNOSIS IN EARLY-STAGE HIGH-RISK BREAST CANCER PATIENTS: Α ΗΕLLENIC COOPERATIVE ONCOLOGY GROUP STUDY.  Kyriaki Pliarchopoulou, Flora Stavridi, Konstantine T. Kalogeras, Ralph M Wirtz, Zoi Alexopoulou, Flora Zagouri, Elke Veltrup, Eleni Timotheadou, Helen Gogas, Angelos Koutras, Christos Christodoulou, George Pentheroudakis, Apostolos Laskarakis, Petroula Arapantoni-Dadioti, Anna Batistatou, Maria Sotiropoulou, Gerasimos Aravantinos, Pavlos Papakostas, Paris Kosmidis, Dimitrios Pectasides, George Fountzilas PloS ONE, Submitted – Under revision

  • INTACT OR BROKEN-APART RNA: AN ALTERNATIVE CONCEPT FOR ALK FUSION SCREENING IN NON-SMALL CELL LUNG CANCER (NSCLC). Kotoula V, Bobos M, Vassilakopoulou M, Tsolaki E, Chrisafi S, Psyrri A, Lazaridis G, Papadopoulou K, Efstratiou I, Michail-Strantzia C, Debelenko LV, Kosmidis P, Fountzilas G. Appl Immunohistochem Mol Morphol. 2015 Jan;23(1):60-70. doi: 10.1097/PAI.0000000000000028.